Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CL Stock Forecast 2026-2027
$83.53
Current Price
$67.02B
Market Cap
Buy 12
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to CL Price Targets
+25.7%
To High Target of $105.00
+17.3%
To Median Target of $98.00
-5.4%
To Low Target of $79.00
CL Price Momentum
-0.7%
1 Week Change
-1.9%
1 Month Change
-11.8%
1 Year Change
+5.7%
Year-to-Date Change
-15.9%
From 52W High of $99.33
+12.0%
From 52W Low of $74.55
📊 TOP ANALYST CALLS
Did CL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Colgate is one of their latest high-conviction picks.
Latest CL Stock Price Targets & Analyst Predictions
Based on our analysis of 30 Wall Street analysts, CL has a bullish consensus with a median price target of $98.00 (ranging from $79.00 to $105.00). The overall analyst rating is Buy (7.9/10). Currently trading at $83.53, the median forecast implies a 17.3% upside. This outlook is supported by 12 Buy, 7 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Filippo Falorni at Citigroup, projecting a 25.7% upside. Conversely, the most conservative target is provided by Lauren Lieberman at Barclays, suggesting a 5.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CL Analyst Ratings
12
Buy
7
Hold
0
Sell
CL Price Target Range
Low
$79.00
Average
$98.00
High
$105.00
Current: $83.53
Latest CL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 17, 2026 | JP Morgan | Andrea Teixeira | Overweight | Maintains | $95.00 |
| Apr 14, 2026 | Barclays | Lauren Lieberman | Equal-Weight | Maintains | $79.00 |
| Apr 10, 2026 | B of A Securities | Bryan Spillane | Buy | Maintains | $102.00 |
| Apr 8, 2026 | Wells Fargo | Chris Carey | Equal-Weight | Maintains | $92.00 |
| Apr 8, 2026 | Piper Sandler | Michael Lavery | Overweight | Maintains | $92.00 |
| Apr 7, 2026 | UBS | Peter Grom | Buy | Maintains | $98.00 |
| Mar 30, 2026 | Deutsche Bank | Steve Powers | Buy | Upgrade | $98.00 |
| Feb 3, 2026 | Barclays | Lauren Lieberman | Equal-Weight | Maintains | $88.00 |
| Feb 2, 2026 | Piper Sandler | Michael Lavery | Overweight | Maintains | $96.00 |
| Feb 2, 2026 | Citigroup | Filippo Falorni | Buy | Maintains | $105.00 |
| Feb 2, 2026 | JP Morgan | Andrea Teixeira | Overweight | Maintains | $97.00 |
| Feb 2, 2026 | B of A Securities | Bryan Spillane | Buy | Maintains | $100.00 |
| Feb 2, 2026 | Deutsche Bank | Steve Powers | Hold | Maintains | $90.00 |
| Feb 2, 2026 | Morgan Stanley | Dara Mohsenian | Overweight | Maintains | $100.00 |
| Feb 2, 2026 | Evercore ISI Group | Robert Ottenstein | Outperform | Maintains | $100.00 |
| Feb 2, 2026 | Wells Fargo | Chris Carey | Equal-Weight | Maintains | $94.00 |
| Feb 2, 2026 | Jefferies | Kaumil Gajrawala | Hold | Maintains | $91.00 |
| Jan 16, 2026 | JP Morgan | Andrea Teixeira | Overweight | Maintains | $93.00 |
| Jan 14, 2026 | UBS | Peter Grom | Buy | Maintains | $93.00 |
| Jan 13, 2026 | Wells Fargo | Chris Carey | Equal-Weight | Upgrade | $86.00 |
Colgate-Palmolive Co (CL) Competitors
The following stocks are similar to Colgate based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Colgate-Palmolive Co (CL) Financial Data
Colgate-Palmolive Co has a market capitalization of $67.02B with a P/E ratio of 32.6x. The company generates $20.38B in trailing twelve-month revenue with a 10.5% profit margin.
Revenue growth is +5.8% quarter-over-quarter, while maintaining an operating margin of +20.4% and return on equity of +497.5%.
Valuation Metrics
Market Cap
$67.02B
Enterprise Value
$76.25B
P/E Ratio
32.6x
PEG Ratio
-0.3x
Price/Sales
3.4x
Growth & Margins
Revenue Growth (YoY)
+5.8%
Gross Margin
+60.2%
Operating Margin
+20.4%
Net Margin
+10.5%
EPS Growth
+5.8%
Financial Health
Cash/Price Ratio
+2.1%
Current Ratio
0.8x
Debt/Equity
2,343.6x
ROE
+497.5%
ROA
+16.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Colgate-Palmolive Co (CL) Business Model
About Colgate-Palmolive Co
What They Do
Produces and markets household and personal care products.
Business Model
Colgate-Palmolive operates primarily through two segments: Oral, Personal and Home Care, and Pet Nutrition. The company generates revenue by selling a wide range of essential household and personal care products, as well as premium pet food, with a significant portion of sales coming from international markets.
Additional Information
Founded in 1806, Colgate-Palmolive has a strong global presence in over 200 countries, with approximately 70% of its business from international markets, including 45% from emerging regions. The company reported revenues of $20.10 billion in 2024 and employs around 34,000 people, indicating its crucial role in the consumer defensive sector.
Company Information
Sector
Consumer Defensive
Industry
Household & Personal Products
Employees
33,600
CEO
Mr. Noel R. Wallace
Country
United States
IPO Year
1977
Website
www.colgatepalmolive.comColgate-Palmolive Co (CL) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Procter & Gamble's EPS Growth Story: Sustainable or Slowing Ahead?
PG leans on pricing power, digital supply chain upgrades and cost discipline to sustain margins, though near-term EPS growth may face pressure.
Apr 20, 2026
By Rashmi Jaiswal
Analyst Blog
Colgate-Palmolive (CL) Earnings Expected to Grow: Should You Buy?
Colgate-Palmolive (CL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 17, 2026
By Zacks Equity Research
Tale of the Tape
Procter & Gamble Pre-Q3 Earnings: Wise to Buy It Before the Release?
PG heads into Q3 earnings release, with sales and EPS seen rising, but tariffs, commodity costs and a premium valuation could pressure margins.
Apr 17, 2026
By Rajani Lohia
Analyst Blog
Latest News
Colgate-Palmolive Webcasts 2026 First Quarter Earnings Conference Call May 1, 2026 – 8:30 a.m. ET
4 days ago
Quick Summary
Colgate-Palmolive will host a live webcast of its Q1 2026 earnings call on May 1, 2026, at 8:30 a.m. ET, featuring key executives including CEO Noel Wallace.
Why It Matters
The webcast announcement indicates Colgate-Palmolive's commitment to transparency and communication, which can influence investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Colgate-Palmolive (CL) may not meet earnings expectations in its upcoming report due to lacking key factors for a likely earnings beat. Investors should prepare accordingly.
Why It Matters
Colgate-Palmolive's potential earnings miss may lead to a drop in stock price, affecting investor sentiment and valuation, as it signals weaker than expected performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Procter & Gamble and Colgate-Palmolive reported quarterly earnings in January, highlighting differences between two leading dividend-paying consumer staples companies.
Why It Matters
Quarterly earnings highlight performance differences between Procter & Gamble and Colgate-Palmolive, influencing investor sentiment and potential dividend stability in the consumer staples sector.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
Quick Summary
The business is currently performing well in 2026, indicating strong financial results or growth relative to expectations or competitors.
Why It Matters
Outperformance in 2026 indicates strong financial health and growth potential, suggesting possible stock appreciation and increased investor confidence.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
CL anticipates tariff fluctuations until 2026, focusing on supply-chain adjustments, pricing strategies, and productivity improvements to protect profit margins.
Why It Matters
Tariff volatility may impact costs and profitability for CL. Their strategies on supply-chain adjustments and pricing could influence future margins, affecting stock performance and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Top Stock Picks 2026: Q1 Progress Report
14 days ago
Quick Summary
The Dow, S&P 500, and Nasdaq reported quarterly losses for the second consecutive year and the third time in five years at the start of the calendar year.
Why It Matters
Quarterly losses in major indexes signal potential market volatility, affecting investor sentiment and strategies, which could influence stock prices and investment decisions.
Source: Schaeffers Research
Market Sentiment:
Neutral
Frequently Asked Questions About CL Stock
What is Colgate-Palmolive Co's (CL) stock forecast for 2026?
Based on our analysis of 30 Wall Street analysts, Colgate-Palmolive Co (CL) has a median price target of $98.00. The highest price target is $105.00 and the lowest is $79.00.
Is CL stock a good investment in 2026?
According to current analyst ratings, CL has 12 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $83.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CL stock?
Wall Street analysts predict CL stock could reach $98.00 in the next 12 months. This represents a 17.3% increase from the current price of $83.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Colgate-Palmolive Co's business model?
Colgate-Palmolive operates primarily through two segments: Oral, Personal and Home Care, and Pet Nutrition. The company generates revenue by selling a wide range of essential household and personal care products, as well as premium pet food, with a significant portion of sales coming from international markets.
What is the highest forecasted price for CL Colgate-Palmolive Co?
The highest price target for CL is $105.00 from Filippo Falorni at Citigroup, which represents a 25.7% increase from the current price of $83.53.
What is the lowest forecasted price for CL Colgate-Palmolive Co?
The lowest price target for CL is $79.00 from Lauren Lieberman at Barclays, which represents a -5.4% decrease from the current price of $83.53.
What is the overall CL consensus from analysts for Colgate-Palmolive Co?
The overall analyst consensus for CL is bullish. Out of 30 Wall Street analysts, 12 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $98.00.
How accurate are CL stock price projections?
Stock price projections, including those for Colgate-Palmolive Co, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 4:16 PM UTC